Maze Therapeutics, Inc Common Stock

Maze Therapeutics, Inc Common Stock

Yahoo Finance • 5 hours ago

Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?

Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfol... Full story

Yahoo Finance • 3 days ago

The Surprise That Sent Vertex — And Its Chief Rival — Soaring

Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs. Continue Reading... Full story

Yahoo Finance • 3 months ago

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?

Jason V. Coloma, Chief Executive Officer of Maze Therapeutics (NASDAQ:MAZE), reported the indirect sale of 27,858 shares of common stock over three open-market transactions on June 22 and June 23, 2026, according to the SEC Form 4 filing.... Full story

Yahoo Finance • 4 months ago

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

On May 15, 2026, HighVista Strategies disclosed it sold 70,503 shares of Maze Therapeutics(NASDAQ:MAZE) in Q1 2026, an estimated $3.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange... Full story

Yahoo Finance • 4 months ago

Maze Therapeutics GAAP EPS of -$0.45 beats by $0.10, revenue of $20M beats by $11.5M

* Maze Therapeutics press release [https://seekingalpha.com/pr/20512103-maze-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights] (MAZE [https://seekingalpha.com/symbol/MAZE]): Q1 GAAP EPS of -$0.45 beats by $... Full story

Yahoo Finance • 5 months ago

Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials

Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics(NASDAQ:MAZE), reported the exercise and immediate sale of 7,500 shares of common stock for a transaction value of approximately $190,000 on April 29, 2026, as disclose... Full story

Yahoo Finance • 5 months ago

What Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to Buy

Maze Therapeutics Inc. (NASDAQ:MAZE) is one of the 10 oversold small cap stocks to buy now. As of the April 24 closing, the consensus sentiment around the stock was strongly bullish. It received Buy ratings from all 12 analysts who provid... Full story

Yahoo Finance • 5 months ago

Maze Therapeutics prices $150M equity offering

Maze Therapeutics (MAZE [https://seekingalpha.com/symbol/MAZE]) has priced [https://seekingalpha.com/pr/20482399-maze-therapeutics-announces-150-million-registered-offering]its underwritten registered offering of 5.54M shares of its common... Full story

Yahoo Finance • 5 months ago

Maze Therapeutics Announces $150 Million Registered Offering

SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per s... Full story

Yahoo Finance • 6 months ago

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.

Key Points Chief Medical Officer Harold Bernstein sold 15,000 company shares for a transaction value of ~$442,000 at around $29.46 per share on April 1, 2026. This disposition represented 100% of Harold Bernstein's direct Common Stock hol... Full story

Yahoo Finance • 6 months ago

Maze Therapeutics falls despite positive mid-stage trial data for lead asset

[An arrow pointing downwards on top of a pile of US dollar bills.] Maze Therapeutics (MAZE [https://seekingalpha.com/symbol/MAZE]) plunged ~37% on Wednesday despite reporting encouraging initial data from a Phase 2 trial for its lead asse... Full story

Yahoo Finance • 6 months ago

Block upgraded, Starbucks downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Truist upgraded Block (XYZ) to Buy fro... Full story

Yahoo Finance • 7 months ago

Qualcomm downgraded, Rivian upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: TD Cowen upgraded Rivian (RIVN) to Buy f... Full story

Yahoo Finance • 7 months ago

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment... Full story

Yahoo Finance • 11 months ago

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 Enrollment ongoing in... Full story

Yahoo Finance • 12 months ago

Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseas... Full story

Yahoo Finance • last year

What's going on in today's session

Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] GAINERS TICKER CHANGE COMMENT VNCE [https://www.chartmill.com/stock/quote/VNCE/profile] 113.0% VINCE H... Full story

Yahoo Finance • last year

Which stocks are moving on Thursday?

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] GAINERS TICKER CHANGE COMMENT VNCE [ht... Full story

Yahoo Finance • last year

Thursday's session: gap up and gap down stocks

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT VNCE [https://www.chartmill.com/stock/q... Full story

Yahoo Finance • last year

Discover the top movers in Thursday's pre-market session.

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT YYGH [https://www.chartmill... Full story